Literature DB >> 1854455

Angiotensin II receptor heterogeneity.

W F Herblin1, A T Chiu, D E McCall, R J Ardecky, D J Carini, J V Duncia, L J Pease, P C Wong, R R Wexler, A L Johnson.   

Abstract

The possibility of receptor heterogeneity in the angiotensin II (AII) system has been suggested previously, based on differences in Kd values or sensitivity to thiol reagents. One of our earliest indications was the frequent observation of incomplete inhibition of the binding of AII to adrenal cortical membranes. Autoradiographic studies demonstrated that all of the labeling of the rat adrenal was blocked by unlabeled AII or saralasin, but not by DuP 753. The predominant receptor in the rat adrenal cortex (80%) is sensitive to dithiothreitol (DTT) and DuP 753, and is designated AII-1. The residual sites in the adrenal cortex and almost all of the sites in the rat adrenal medulla are insensitive to both DTT and DuP 753, but were blocked by EXP655. These sites have been confirmed by ligand binding studies and are designated AII-2. The rabbit adrenal cortex is unique in yielding a nonuniform distribution of AII-2 sites around the outer layer of glomerulosa cells. In the rabbit kidney, the sites on the glomeruli are AII-1, but the sites on the kidney capsule are AII-2. Angiotensin III appears to have a higher affinity for AII-2 sites since it inhibits the binding to the rabbit kidney capsule but not the glomeruli. Elucidation of the distribution and function of these diverse sites should permit the development of more selective and specific therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854455     DOI: 10.1093/ajh/4.4.299s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

1.  Myometrial angiotensin II receptor subtypes change during ovine pregnancy.

Authors:  B E Cox; M A Ipson; P W Shaul; K E Kamm; C R Rosenfeld
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

2.  Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein.

Authors:  J S Zhang; J C Van Meel; M Pfaffendorf; P A Van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

3.  Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule.

Authors:  H F Cheng; B N Becker; K D Burns; R C Harris
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 4.  The clinical potential of renin inhibitors and angiotensin antagonists.

Authors:  R J Cody
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

5.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.

Authors:  L Criscione; M de Gasparo; P Bühlmayer; S Whitebread; H P Ramjoué; J Wood
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

6.  Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.

Authors:  R Cirillo; A R Renzetti; P Cucchi; M Guelfi; A Salimbeni; S Caliari; A Castellucci; S Evangelista; A Subissi; A Giachetti
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

7.  Angiotensin II type 1 receptor expression in human breast tissues.

Authors:  E R Inwang; J R Puddefoot; C L Brown; A W Goode; S Marsigliante; M M Ho; J G Payne; G P Vinson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.